“…1 The notion that LRNB can spontaneously regress has been confirmed by autopsy studies, and this challenges the systematic use of surgical resection. 10,17 Surgical resection cannot always prevent tumor recurrence (as in two cases in our series) and carries a risk, albeit low, of peri-or postoperative complications such as iatrogenic nephrectomy, vascular accidents resulting in vanishing kidney, and intestinal infarction. 18 It is, however, the only way of obtaining a firm diagnosis of MIBG negative nonsecretory tumors.…”
“…1 The notion that LRNB can spontaneously regress has been confirmed by autopsy studies, and this challenges the systematic use of surgical resection. 10,17 Surgical resection cannot always prevent tumor recurrence (as in two cases in our series) and carries a risk, albeit low, of peri-or postoperative complications such as iatrogenic nephrectomy, vascular accidents resulting in vanishing kidney, and intestinal infarction. 18 It is, however, the only way of obtaining a firm diagnosis of MIBG negative nonsecretory tumors.…”
“…In contrast, when it concerns a heterogeneous cyst related to hemorrhage of a CNB, the cyst may evolve into a tumor of complex echogenicity after resolution of the hematoma [24]. For these reasons, it is necessary to repeat US examinations during pregnancy [31][32][33][34].…”
Section: Discussionmentioning
confidence: 99%
“…This raises the problem of the mass size. Holgersen et al [31] have reported 3 cases of small AH (!15 mm), and they suggested that a short course of close observation has no adverse impact on the outcome of these patients with tumors !30 mm in size. Moreover, most of the CNB reported in the literature [1, 9-12, 15, 18, 20, 24, 25, 27] are tumors 130 mm, and this threshold size should be discussed.…”
Section: Discussionmentioning
confidence: 99%
“…The observation period ranged from 6 to 12 weeks of age [27,31]. If cysts do not decrease significantly in size after delivery, or in the presence of abnormal levels of catecholamines, surgical excision of the tumor seems to be advisable.…”
Objectives: The prenatal finding of a large cystic adrenal mass raises the dilemma of the differential diagnosis between adrenal hemorrhage and cystic neuroblastoma. The possibility of a neuroblastoma usually leads to surgical excision of such tumors. Nevertheless, an adrenal hemorrhage has to be recognized, so that unnecessary surgery may be avoided. Methods: Three cases of large prenatally detected adrenal masses managed nonoperatively are reported. Data studied were: age at the diagnosis, prenatal and postnatal ultrasonographic consistency, and tumor marker levels. Size and sonographic evolution were also studied. Results: In all 3 cases, a cystic mass, measuring more than 40 mm in size, was detected during the 3rd trimester of pregnancy. The sonographic appearance evolved from a sonolucent tumor to a heterogeneous mass with hyperechoic areas. The tumor marker levels were normal. All infants had a documented decrease in mass size at birth and were managed nonoperatively. All these tumors were considered adrenal hemorrhages. Conclusions: Prenatal ultrasonography rarely permits to distinguish an adrenal hemorrhage from a cystic neuroblastoma. The differential diagnosis, even in large masses, is based on close postnatal follow-up with serial sonography. Surgery is not mandatory, unless the size does not decrease. However, without pathologic proof, it is not possible to differentiate an adrenal hemorrhage from a spontaneously resolved neuroblastoma.
“…Клинически нейробластома -чрезвычайно гетерогенная опухоль -может спонтанно рег-рессировать или созревать без лечения [4,5], что позволяет занять выжидательную позицию (стратегия «see and wait») 1 [6,7]. Однако возмож-ны агрессивное течение и резистентность к совре-менной интенсивной мультимодальной терапии [8].…”
Treatment of High-Risk Neuroblastoma
Background: Neuroblastoma is one of the most common tumors in children occupying the third place among all malignant neoplasms, trailing only the tumors of the central nervous topotecan, cyclophosphamide, vincristine, doxorubicin, cisplatin, etoposide; in group II (n=13; vincristine, doxorubicin, cyclophosphamide, platidiam, etoposide, carboplatin
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.